Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study.

Framingham Heart Study, Burlington, Mass, USA.
Circulation (Impact Factor: 14.95). 01/2003; 107(3):448-54.
Source: PubMed

ABSTRACT Although insulin resistance has been implicated in the pathogenesis of left ventricular (LV) hypertrophy, previous studies have yielded inconsistent results and are limited by referral bias.
We examined the relations between echocardiographic LV measurements and glucose tolerance status in 2623 Framingham Study subjects (1514 women, mean age 53 years) free of myocardial infarction and heart failure. We also evaluated the relations of insulin resistance (homeostasis model, HOMA-IR) and LV and left atrial (LA) measures within the normal and abnormal glucose tolerance categories (the latter included impaired glucose tolerance, impaired fasting glucose, and newly diagnosed diabetes). LV mass (adjusted for age, height, heart rate, and systolic blood pressure) increased across categories of worsening glucose tolerance; the trend was more striking in women (P<0.001) compared with men (P=0.054). In subjects with normal (n=2022) and abnormal glucose tolerance (n=327), covariate-adjusted LV mass and LV wall thickness increased across HOMA-IR quartiles in women (P<0.001) but not men. In contrast, covariate-adjusted LA size increased with worsening glucose tolerance and across HOMA-IR quartiles in the normal and abnormal glucose tolerance groups in both sexes. Adjustment for body mass index considerably attenuated the relations of LV/LA measures and HOMA-IR, rendering them statistically nonsignificant in the normal glucose tolerance group.
In our large community-based sample, LV mass and wall thickness increased with worsening glucose intolerance, an effect that was more striking in women compared with men. Insulin resistance was associated with increased LV mass in women alone, but this relation was largely accounted for by obesity.

Download full-text


Available from: Helen Parise, Jan 21, 2014
1 Follower
  • Source
    • "The Latin-American Diabetes Association (ALAD) Clinical Guides [12] [13] as well as the Clinical Guide from Chilean Health Ministry suggested the diagnosis of IFG when the fasting plasma glucose is between 100 and 125 mg/dL [14]. Beyond the differences existing in order to establish the normal limit for fasting plasma glucose, the evidences coincide that glucose levels in the stage of prediabetic keep a direct relation with the risk of developing diabetes in the future, and this also constitutes an independent risk factor for cardiovascular diseases (CVD) [15] [16]. Both conditions, T2DM and CVD, are related with other factors such as dyslipidemia , arterial hypertension (HTA), abdominal obesity, sedentary, oxidative stress, metabolic syndrome (MS), and family data [17] [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To study the evolution of impaired fasting glucose (IFG), considering glucose and HbA1c levels and risk factors associated, in a period of 6 years. Methods. We studied 94 subjects with impaired fasting glucose (IFG) that were diagnosed in 2005 and followed up to 2012. Glucose and HbA1c levels were determined. A descriptive analysis of contingence charts was performed in order to study the evolution in the development of type-2 diabetes mellitus (T2DM). Results. Twenty-eight of ninety-four subjects became T2DM; 51/94 remained with IFG; and 20/94 presented normal fasting glucose. From the 28 diabetic subjects, 9 had already developed diabetes and were under treatment with oral hypoglycemic agents; 5 were diagnosed with plasma glucose < 126 mg/dL, but with HbA1c over 6.5%. In those who developed diabetes, 15/28 had a family history of T2DM in first relative degree. Also, diabetic subjects had a BMI significantly higher than nodiabetics (t test: P < 0.01). The individuals that in 2005 had the highest BMI are those who currently have diabetes. Conclusion. The IFG constitutes a condition of high risk of developing T2DM in a few years, especially over 110 mg/dL and in obesity patients.
    Journal of Diabetes Research 08/2014; 2014:710370. DOI:10.1155/2014/710370 · 3.54 Impact Factor
  • Source
    • "Small cardiac vessels' disease • Microvascular remodeling • Impaired coronary flow reserve • Endothelial dysfunction d. Disorders of the autonomous nerve system of the heart • Sympathetic cardiac aponeurosis • Hypercatecholaminemia e. Myocardial fibrosis, apoptosis, necrosis • Activation of the neurohormonal axis • Overexpression of the inflammatory process • Oxidative stress fasting plasma insulin level was found to be the strongest independent predictor of cardiac mass, both in the normotensive and hypertensive diabetic subgroups (de Kreutzenberg , Avogaro, Tiengo, & Del Prato, 2000), while in the Framingham Study insulin resistance was associated with increased LV mass mainly in women, but this relation was largely accounted for by obesity (Rutter et al., 2003). (c) Small cardiac vessels' disease with both structural and functional disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus is a powerful risk factor for cardiovascular disease associated with high morbidity and mortality rates. Diabetic patients also have an increased incidence of heart failure which has been traditionally attributed to the concurrent presence of ischemic or hypertensive heart disease. Yet, nowadays, according to recent scientific evidence, diabetic myocardial disease (DMD) is more and more being considered as a distinct nosologic entity, independent of the co-existence of coronary artery disease, arterial hypertension or other risk factors, with the potential to lead to a self-existent progressive development of heart failure. In this article, we review the possible pathophysiologic mechanisms involved in the development of DMD as well as the structural and functional changes in the diabetic heart. We emphasize the importance of early detection of the syndrome, especially by novel echocardiographic techniques. Finally, we refer to the various therapeutic options for the optimal management of DMD according to the recent literature.
    Journal of diabetes and its complications 02/2008; 23(4):273-82. DOI:10.1016/j.jdiacomp.2007.12.005 · 1.93 Impact Factor
  • Source
    • "In the Strong Heart study of American Indians, an ethnic group known to have a higher prevalence of insulin resistance, impaired glucose tolerance and T2DM were found to be associated with myocardial hypertrophy and systolic and diastolic dysfunction [42]. Similarly, in the Framingham Heart Study, a direct correlation was observed between insulin resistance and echocardiographically determined left ventricular mass, with significant ventricular hypertrophy found in insulin-resistant patients [43]. In a pathologic study, Sharma and colleagues [44] found that intramyocellular lipid overload was present in 30% of non-ischemic failing hearts in biopsy specimens. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin resistance is a nearly universal finding in morbid obesity. It may be compensated and latent or uncompensated with single or multiple clinical abnormalities. Although lifestyle interventions and medical measures alone may control most metabolic problems in the short term, the ultimate benefits of such an approach are usually limited by the complexity of available therapeutic regimens and the difficulty of maintaining full patient compliance. Many studies now document that bariatric surgery can effectively and safely control these complications in the short term and long term or even prevent their occurrence. Further investigations are needed to understand better the mechanisms involved and to define more clearly the appropriate indications and contraindications of the treatments proposed.
    Medical Clinics of North America 06/2007; 91(3):393-414, x. DOI:10.1016/j.mcna.2007.01.005 · 2.80 Impact Factor
Show more